In the first clinical trial of EGFRvIII-directed CAR T cells for GBM, a significant decrease in EGFRvIII expression was demonstrated in almost all patients in which tumor-infiltrating CAR T cells were detected, but not in wild-type EGFR [89]. This evidence concerns the gene EGFR and glioblastoma.